Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ABMT OTCMKTS:ADYX OTCMKTS:AKSY OTCMKTS:FSNUY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABMTAdvanced Biomedical Technologies$0.00$0.00▼$0.00N/A1.561,100 shsN/AADYXAlliqua BioMedical$0.00+∞$0.00$0.00▼$0.00N/A1.9818 shs2,200 shsAKSYAksys$0.00$0.00▼$0.00N/AN/AN/AN/AFSNUYFresenius SE & Co.$12.000.0%$12.36$8.12▼$12.97$26.80B0.7553,322 shs36,757 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABMTAdvanced Biomedical Technologies0.00%0.00%-75.00%-75.00%-83.33%ADYXAlliqua BioMedical0.00%0.00%0.00%0.00%0.00%AKSYAksys0.00%0.00%0.00%0.00%0.00%FSNUYFresenius SE & Co.-2.52%-2.76%-5.36%+7.26%+50.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABMTAdvanced Biomedical TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AADYXAlliqua BioMedicalN/AN/AN/AN/AN/AN/AN/AN/AAKSYAksysN/AN/AN/AN/AN/AN/AN/AN/AFSNUYFresenius SE & Co.N/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABMTAdvanced Biomedical Technologies 0.00N/AN/AN/AADYXAlliqua BioMedical 0.00N/AN/AN/AAKSYAksys 0.00N/AN/AN/AFSNUYFresenius SE & Co. 3.33BuyN/AN/ACurrent Analyst Ratings BreakdownLatest FSNUY, ABMT, AKSY, and ADYX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025FSNUYFresenius SE & Co.Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABMTAdvanced Biomedical Technologies$270KN/AN/AN/AN/AN/AADYXAlliqua BioMedicalN/AN/AN/AN/AN/AN/AAKSYAksysN/AN/AN/AN/AN/AN/AFSNUYFresenius SE & Co.$23.63B1.13$1.26 per share9.52$9.83 per share1.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABMTAdvanced Biomedical Technologies-$510KN/A0.00N/AN/AN/AN/AN/AN/AADYXAlliqua BioMedicalN/AN/A0.00∞N/AN/AN/AN/AN/AAKSYAksysN/AN/A0.00N/AN/AN/AN/AN/AN/AFSNUYFresenius SE & Co.$509.67M$0.1963.1313.04N/A1.92%9.06%4.17%7/30/2025 (Estimated)Latest FSNUY, ABMT, AKSY, and ADYX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025FSNUYFresenius SE & Co.$0.2170$0.23+$0.0130$0.11$5.41 billion$5.92 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABMTAdvanced Biomedical TechnologiesN/AN/AN/AN/AN/AADYXAlliqua BioMedicalN/AN/AN/AN/AN/AAKSYAksysN/AN/AN/AN/AN/AFSNUYFresenius SE & Co.$0.181.50%N/A94.74%N/ALatest FSNUY, ABMT, AKSY, and ADYX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/22/2025FSNUYFresenius SE & Co.$0.18271.48%5/27/20255/28/20256/4/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABMTAdvanced Biomedical TechnologiesN/AN/AN/AADYXAlliqua BioMedicalN/AN/AN/AAKSYAksysN/AN/AN/AFSNUYFresenius SE & Co.0.501.431.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABMTAdvanced Biomedical TechnologiesN/AADYXAlliqua BioMedicalN/AAKSYAksysN/AFSNUYFresenius SE & Co.N/AInsider OwnershipCompanyInsider OwnershipABMTAdvanced Biomedical Technologies34.11%ADYXAlliqua BioMedical17.40%AKSYAksys3.80%FSNUYFresenius SE & Co.N/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABMTAdvanced Biomedical Technologies20N/AN/ANot OptionableADYXAlliqua BioMedical6N/AN/ANot OptionableAKSYAksys87N/AN/ANot OptionableFSNUYFresenius SE & Co.176,4862.23 billionN/ANot OptionableFSNUY, ABMT, AKSY, and ADYX HeadlinesRecent News About These CompaniesFresenius launches denosumab biosimilarsJuly 8, 2025 | drugstorenews.comDFresenius Medical in-pact with Coordination of National Institutes in MexicoJuly 3, 2025 | msn.comFSNUY Fresenius SE & Co. KGaA - Seeking AlphaJune 28, 2025 | seekingalpha.comFresenius Medicare Drug Sales Tax Win Upheld by Louisiana CourtJune 26, 2025 | news.bloomberglaw.comNFresenius SE & Co. (OTCMKTS:FSNUY) Shares Down 2.8% - Should You Sell?June 17, 2025 | marketbeat.comFresenius: Healthy Portfolio AddJune 7, 2025 | seekingalpha.comFresenius SE price target raised to EUR 52 from EUR 43 at CitiJune 5, 2025 | msn.comThree Days Left Until Fresenius SE & Co. KGaA (ETR:FRE) Trades Ex-DividendMay 22, 2025 | finance.yahoo.comBerenberg Increases Price Target for Fresenius SE (FSNUY) | FSNUY Stock NewsMay 12, 2025 | gurufocus.comFresenius SE & Co. KGaA (FSNUF) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comFresenius SE Reports Strong Start to 2025 EarningsMay 8, 2025 | tipranks.comGermany's Fresenius reports rise in earnings in first quarterMay 7, 2025 | msn.comRetail investors who hold 37% of Fresenius SE & Co. KGaA (ETR:FRE) gained 5.9%, institutions profited as wellMay 1, 2025 | finance.yahoo.comFresenius responds to union allegationsApril 24, 2025 | ivpressonline.comIFresenius Medical Care (ETR:FME) Is Paying Out A Larger Dividend Than Last YearApril 9, 2025 | finance.yahoo.comFresenius’ Misconduct Defense Fails in PharmaSphere Patent CaseApril 2, 2025 | news.bloomberglaw.comNFresenius: Turnaround For Company, Stock PriceMarch 16, 2025 | seekingalpha.comFresenius Raises €1.1 Billion for Stake in Dialysis CompanyMarch 4, 2025 | finance.yahoo.comFresenius Continues Growth of Biosimilars Portfolio with the U.S. Availability of Otulfi® (ustekinumab-aauz)March 3, 2025 | finance.yahoo.comFresenius Seeks €1.1 Billion for Stake in Dialysis CompanyMarch 3, 2025 | bloomberg.comFresenius SE Stock: Strong Recovery Drives Growth and DividendsFebruary 26, 2025 | aktiencheck.deAMedia Sentiment Over TimeFSNUY, ABMT, AKSY, and ADYX Company DescriptionsAdvanced Biomedical Technologies OTCMKTS:ABMTAdvanced Biomedical Technologies, Inc., a development stage company, designs, develops, manufactures, and markets biomaterial internal fixation devices. It offers polymer osteosynthesis devices, such as surgical screws, binding wires, rods, and related medical devices for the treatment of orthopedic trauma, sports-related medical treatment, cartilage repair, and related treatments, as well as for reconstructive dental procedures. The company was formerly known as Geostar Mineral Corporation and changed its name to Advanced Biomedical Technologies, Inc. in March 2009. Advanced Biomedical Technologies, Inc. was founded in 2002 and is based in New York, New York.Alliqua BioMedical OTCMKTS:ADYX$0.0001 +0.00 (+∞) As of 07/15/2025 05:20 PM EasternAdynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.Aksys OTCMKTS:AKSYAksys Ltd. provides hemodialysis products and services for patients suffering from end-stage renal disease, known as chronic kidney failure. The company offers an automated personal hemodialysis system, known as the Aksys PHD, a Personal Hemodialysis System (PHD System), which is designed to enable patients to perform frequent hemodialysis at alternate sites, such as their own homes. The PHD System is designed to monitor, during the treatment, various vital statistics, including the patient's blood flow rate, the amount of water removed from the patient, the length of the treatment session, and other parameters. It also evaluates the performance of the artificial kidney in removing toxins from the patient's blood prior to each treatment, as well as automatically evaluates the water treatment filters and indicates whether a replacement is required and verifies that safety systems, sensors, and alarms are operating correctly. Aksys Ltd. also provides various services, including the delivery and installation of the PHD System; technical services, including maintenance and repair of the PHD System; delivery of consumables used in dialysis, such as the water purification components and dialysate concentrate; and artificial kidney, and arterial and venous blood tubing. The company markets its products and services, primarily to healthcare providers, such as hospitals, dialysis clinics, managed care organizations, and nephrology physician groups in the United States, the United Kingdom, and Japan. Aksys Ltd. was founded in 1991 and is headquartered in Lincolnshire, Illinois.Fresenius SE & Co. OTCMKTS:FSNUY$12.00 -0.01 (-0.04%) As of 03:50 PM EasternFresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
